May 20, 2008 by Brian LawlerExelixis Looking ExcellentThe drugmaker reveals promising news on multiple drugs in development.
May 15, 2008 by Brian LawlerWhat's Cooking at Flamel?The drugmaker searches for partners as a label expansion moves forward.
May 15, 2008 by Brian LawlerYou're Kidding Me, Cardiome!The pharmaceutical's still awaiting an FDA decision on its lead drug.
May 14, 2008 by Brian LawlerTeaching Old Drugs New TricksPfizer's top drugs post mixed results in recent off-label studies.
May 13, 2008 by Brian LawlerSanofi Can't Shake the GenericsA new threat to the pharmaceutical's top drug may have arrived.
May 12, 2008 by Brian LawlerHep C Drugs Slug It OutDoes Vertex's telaprevir really trump Schering's boceprevir?
May 7, 2008 by Brian LawlerCephalon's Long Shot Falls ShortAn FDA advisory panel brings bad news for the company.
May 6, 2008 by Brian LawlerMannKind Moves AheadThe pharmaceutical awaits pivotal safety data on its lead drug.
May 5, 2008 by Brian LawlerGood News for Abuse-Resistant DrugsThe FDA has few objections to a potential new class of pain drugs.
May 1, 2008 by Brian LawlerGlaxo's Global Growth GambitThe pharmaceutical's new CEO has changes in mind.
May 1, 2008 by Brian LawlerSoliris Brightens Alexion's QuarterThe pharmaceutical's lone drug posts gargantuan growth.
Apr 30, 2008 by Brian LawlerBioMarin's Bodacious EarningsCan't complain about this quarter's numbers.
Apr 30, 2008 by Brian LawlerA Dominating Danish DrugmakerNovo Nordisk turns in solid first-quarter financial numbers.
Apr 30, 2008 by Brian LawlerAlexza Advances 2 More DrugsThe pharmaceutical's compounds keep zipping through clinical trials.
Apr 30, 2008 by Brian LawlerAdditional Aggravation for AngiotechCould any drugmaker have a worse start to the year?
Apr 30, 2008 by Brian LawlerIdenix Aims for a ComebackThis drugmaker may be down, but it's not yet out.
Apr 30, 2008 by Brian LawlerViroPharma: Risky and ExcitingSolid lead drug, meet promising pipeline candidate.
